$IBIO

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an

iBio, Inc. (IBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesi

iBio (NASDAQ: IBIO) reported preclinical obese NHP results for its single-dose Activin E antibody IBIO-610. Active Activin E was suppressed in all treated animals through eight weeks, with ~98% reduction at week 4 and ~97% at week 8. In combination with semaglutide, IBIO-610 increased visceral/total fat loss and cut lean-mass loss by 73% versus semaglutide alone; full data will be presented at EASD 2026.

iBio (NASDAQ: IBIO) said CEO and Chief Scientific Officer Martin Brenner and CFO Felipe Duran will attend the Jefferies Global Healthcare Conference on June 4, 2026 in New York and the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14–15 in Boston. The company will livestream and replay the Jefferies presentation and hold one-on-one investor meetings at Leerink.

iBio (NASDAQ: IBIO) said it dosed the first participant in a Phase 1 trial of IBIO-600, its first obesity/cardiometabolic program to enter human testing. The randomized, double-blind, placebo-controlled single-ascending-dose study will assess safety, tolerability, PK/PD and body-composition effects in ~32 adults with overweight/obesity, with completion expected in 2H 2027.

Logos Global Management and its affiliated entities have filed an amended Schedule 13G/A, declaring 0% beneficial ownership of iBio (NASDAQ: IBIO) common stock. The filing, signed on May 15, 2026, indicates that the reporting persons, including Arsani William, beneficially own 0 shares and expressly disclaim group membership and beneficial ownership under Rule 13d-3. This update clarifies their neutral stance and confirms no intent to change or influence control of iBio.

iBio Inc (IBIO) has released its earnings summary for the quarter that concluded on March 31. The report, distributed by Reuters via TradingView News, provides key financial results for the company during this period. Further details of the earnings report were not included in this brief summary.

iBio's CFO, Felipe Duran, recently acquired 24,835 shares of the company's common stock for approximately $50,131 on March 19, 2026. This insider purchase follows a 162% surge in stock price over the last six months and occurred despite a recent 12.6% weekly drop. Analysts have set price targets between $4.20 and $7.00, indicating significant upside potential for the company.

iBio, Inc. (IBIO) is advancing its pipeline of drugs targeting obesity and cardiovascular diseases. The company's key programs focus on muscle preservation and fat-specific weight loss with improved safety profiles. This progress is supported by strong financial backing and experienced leadership, with clinical milestones anticipated soon.

IBIO is developing next-generation obesity therapies with a focus on muscle preservation and improved safety profiles, supported by strong financial backing through 2028. The company has a robust pipeline with multiple assets nearing clinical trials, and key data readouts and regulatory filings are anticipated within the next 12-24 months. This information is derived from their presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.